167216-22-0

Usage

Uses

1. Pharmaceutical Industry:
Carbamic acid, (3-hydroxy-1,1-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI) is used as an intermediate in the synthesis of various pharmaceutical compounds. It plays a crucial role in the preparation of (2E)-5-(tert-Butyloxycarbonylamino)-5-methylhex-2-enoic Acid (B809765), which is further utilized in the synthesis of C-terminal sulfonamide analogs of NN703. These analogs serve as growth hormone secretagogues, which are important for the treatment of growth hormone deficiencies and related conditions.
2. Chemical Synthesis:
In the field of chemical synthesis, Carbamic acid, (3-hydroxy-1,1-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI) can be used as a building block or a reagent for the development of new compounds with potential applications in various industries, such as agriculture, materials science, and pharmaceuticals. Its unique structure and functional groups make it a valuable component in the synthesis of complex organic molecules.
3. Research and Development:
Due to its unique chemical structure, Carbamic acid, (3-hydroxy-1,1-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI) can be a valuable compound for research and development purposes. It can be used in the study of chemical reactions, mechanisms, and the development of new synthetic methods. Additionally, it may serve as a starting material for the synthesis of novel compounds with potential applications in various fields.

Upstream product

• 42514-50-1 1-hydroxy-3-methylbut-3-ylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 129765-95-3 3-[(tert-butoxycarbonyl)amino]-3-methylbutanoic acid 
• 541-41-3 chloroformic acid ethyl ester 
• 155300-46-2 N-(tert-butoxycarbonyl)-4,4-dimethylazetidin-2-one 
• 17945-55-0 3-Benzylamino-3-methyl-butan-1-ol 
• 26939-09-3 2,4,4-trimethyl-5,6-dihydro-1,3(4H)-oxazine 

Downstream Products

• 181646-38-8 (1,1-dimethyl-3-oxo-propyl)-carbamic acid tert-butyl ester 
• 193079-05-9 (E)-5-Amino-5-methyl-hex-2-enoic acid ((R)-1-{[(R)-1-((R)-2-hydroxy-propylcarbamoyl)-2-phenyl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-amide 
• 193079-05-9 (E)-5-Amino-5-methyl-hex-2-enoic acid ((R)-1-{[(R)-1-((S)-2-hydroxy-propylcarbamoyl)-2-phenyl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-amide 
• 213335-92-3 {(E)-4-[((R)-1-{[(R)-1-((R)-2-Hydroxy-propylcarbamoyl)-2-phenyl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester 
• 213335-84-3 {(E)-4-[((R)-1-{[(R)-1-((S)-2-Hydroxy-propylcarbamoyl)-2-phenyl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester 
• 1027896-29-2 {(E)-4-[((R)-2-Biphenyl-4-yl-1-{[(R)-2-(4-fluoro-phenyl)-1-((R)-2-hydroxy-propylcarbamoyl)-ethyl]-methyl-carbamoyl}-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester 
• 193085-86-8 ((E)-1,1-Dimethyl-4-{methyl-[(R)-1-(methyl-{(R)-2-phenyl-1-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-ethyl}-carbamoyl)-2-naphthalen-1-yl-ethyl]-carbamoyl}-but-3-enyl)-carbamic acid tert-butyl ester 
• 213335-86-5 ((E)-1,1-Dimethyl-4-{methyl-[(R)-1-(methyl-{(R)-2-phenyl-1-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-ethyl}-carbamoyl)-2-naphthalen-2-yl-ethyl]-carbamoyl}-but-3-enyl)-carbamic acid tert-butyl ester 
• 1026241-86-0 {(E)-4-[((R)-2-Biphenyl-4-yl-1-{[(R)-1-((S)-2-hydroxy-propylcarbamoyl)-2-thiophen-2-yl-ethyl]-methyl-carbamoyl}-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester 
• 213335-88-7 {(E)-4-[((R)-1-{[(R)-1-(Cyclopropylmethyl-carbamoyl)-2-phenyl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester 
• 1027547-68-7 {(E)-4-[((R)-1-{[(R)-2-(3,4-Difluoro-phenyl)-1-methylcarbamoyl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester 
• 193085-59-5 {(E)-4-[((R)-1-{[(R)-2-(4-Fluoro-phenyl)-1-methylcarbamoyl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester 
• 1027943-26-5 {(E)-4-[((R)-1-{[(R)-2-(4-Iodo-phenyl)-1-methylcarbamoyl-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester 
• 213335-90-1 [(E)-4-({(R)-1-[((R)-1-Ethylcarbamoyl-2-phenyl-ethyl)-methyl-carbamoyl]-2-naphthalen-2-yl-ethyl}-methyl-carbamoyl)-1,1-dimethyl-but-3-enyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer, reducing inflammation and/or treating an autoimmune or inflammatory disease.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3- dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlogumine; and use of the derivatives and analogs for treating cancer.

BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING SAME

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1 ), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE

Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

3- (SULPHONYLAMINO) -PHENYL-2 -HYDROXY-ETHYLAMINO DERIVATIVES USEFUL AS BETA-AGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENTS

The present invention relates to compounds of general formula (I), wherein the groups A, L, R1 and R2 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, mixtures thereof, so

Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions

The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 to R4 have the meanings given in ths claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates,

Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions

The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 and R2 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates,

Compounds with growth hormone releasing properties

Disclosed are compounds of formula I formula I wherein R1, R2, R5, R6, R7, R8, G, J, L, M, a, b, c, d, e, and f are as defined in the specification, and compositions containing them. These

Method for preparing a compound with growth hormone releasing properties

A method for preparing a compound of formula I or a salt thereof is disclosed.